Clinical Trial Update: Study of LJP 394 in Lupus Patients With History of Renal Disease [Phase 3]

View source ↗

Summary

A Phase 3 study of LJP 394 in patients with systemic lupus erythematosus and a history of renal disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• LJP 394

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 3 | Status: TERMINATED